// App-Quantinova.ai

EP457 : A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Researchers

Presenter

  • Courtney DiNardo

Principal Investigators

  • Andre Schuh

  • Cristina Papayannidis

  • Paresh Vyas

  • Andrew Wei

  • Hans Ommen

  • Sergey Semochkin

  • Hee-Je Kim

  • Richard Larson

  • Jamie Koprivnikar

  • Olga Frankfurt

  • Felicitas Thol

  • Jrg Chromik

  • Jenny Byrne

  • Arnaud Pigneux

  • Xavier Thomas

  • Olga Salamero

  • Maria Belen Vidriales

  • Vadim Doronin

  • Hartmut Dhner

  • Amir Fathi

  • Eric Laille

  • Xin Yu

  • Maroof Hasan

  • Patricia Martin-Regueira

  • Stphane de Botton

Medical Centers

  • The Alfred Hospital, Melbourne, Australia

  • Rush University Medical Center, Chicago, Illinois, United States

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Universitatsklinikum Ulm, Ulm, Germany

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Pirogov Russian National Research Medical University, Moscow, Russia

  • City Clinical Hospital No. 40,Moscow,Russian Federation

  • Gustave Roussy, Villejuif, France

  • University Hospital Vall d'Hebron, Barcelona, Spain

  • Aarhus University Hospital, Aarhus, Denmark

  • John Theurer Cancer Center at Hackensack Univ. Medical Center,Hackensack, NJ,United States

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • IRCCS Azienda ospedaliero-universitaria di Bologna,Istituto di Ematologia 'Seràgnoli',Bologna,Italia

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine,Chicago, IL,États-unis

  • Universitatsklinik Frankfurt Hospital, Frankfurt, Germany

  • Bristol Meyers Squibb,Princeton,United States

  • NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford

  • Harvard Medical School, Boston, MA, United States

  • Medizinische Hochschule Hannover: Zentrum Innere Medizin,Hannover,Germany

  • University Hospital of Salamanca, Salamanca, Spain

  • Deakin University, Melbourne, Australia

  • Bordeaux Haut-Leveque University Hospital,Pessac,France

  • Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea, Republic of (South)

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

Locations

  • Australia

  • United States

  • Canada

  • Germany

  • Russia

  • France

  • Spain

  • Denmark

  • Italy

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Vidaza

  • Enasidenib

  • ara-c

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved